Literature DB >> 9794868

Marketing medicines through randomised controlled trials: the case of interferon.

T Pieters1.   

Abstract

Keywords:  Biomedical and Behavioral Research

Mesh：

Substances：

Year:  1998        PMID： 9794868      PMCID： PMC1114165          DOI： 10.1136/bmj.317.7167.1231

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

1.  Biological response modifiers.

Authors: 
Journal:  Semin Oncol       Date:  1986-06       Impact factor: 4.929

2.  Interferon: no magic bullet against cancer.

Authors:  M Sun
Journal:  Science       Date:  1981-04-10       Impact factor: 47.728

3.  Interferon: cloudy but intriguing future.

Authors:  R S Johnson
Journal:  JAMA       Date:  1981-01-09       Impact factor: 56.272

4.  Interferon: decline and stall.

Authors:  P Newmark
Journal:  Nature       Date:  1981-05-14       Impact factor: 49.962

5.  Use of placebo controls in clinical trials disputed.

Authors:  G Taubes
Journal:  Science       Date:  1995-01-06       Impact factor: 47.728

6.  Interferon and its first clinical trial: looking behind the scenes.

Authors:  T Pieters
Journal:  Med Hist       Date:  1993-07       Impact factor: 1.419
  6 in total
  6 in total

1.  Does participation in clinical trials influence the costs of future management of patients?

Authors:  Anne Hvenegaard; Henrik Hauschildt Juhl; Andreas Habicht
Journal:  Eur J Health Econ       Date:  2011-11-10

Review 2.  Evidence-based ethics for neurology and psychiatry research.

Authors:  Scott Y H Kim
Journal:  NeuroRx       Date:  2004-07

3.  Unbiased, relevant, and reliable assessments in health care: important progress during the past century, but plenty of scope for doing better.

Authors:  I Chalmers
Journal:  BMJ       Date:  1998-10-31

Review 4.  Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.

Authors:  Toon van der Gronde; Carin A Uyl-de Groot; Toine Pieters
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

5.  How to produce 'marketable and profitable results for the company': from viral interference to Roferon A.

Authors:  Carsten Timmermann
Journal:  Hist Philos Life Sci       Date:  2019-07-30       Impact factor: 1.205

6.  Participatory workshops are not enough to prevent policy implementation failures: an example of a policy development process concerning the drug interferon-beta for multiple sclerosis.

Authors:  Margriet Moret-Hartman; Rob Reuzel; John Grin; Gert Jan van der Wilt
Journal:  Health Care Anal       Date:  2007-10-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.